^
Association details:
| Biomarker: | FGFR1 rearrangement |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | Pemazyre (pemigatinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLNFGFR1)
Published date:
11/04/2021
Excerpt:
This is an analysis of data from the ongoing FIGHT-203 study of pemigatinib in adults with MLNFGFR1 (NCT03011372). All primary and secondary endpoints were investigator-assessed according to protocol-defined criteria including modified response criteria for MDS/MPN and modified Lugano criteria for EMD...Pemigatinib is the first therapy to demonstrate durable and high rates of CR and CCyR in pts with MLNFGFR1...
DOI:
10.1182/blood-2021-148103
Trial ID:
